Skip to content
Open in App
Astellas Pharma logo

Astellas Pharma

web2

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pha...

Symbol · 4503
Company profile

About

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

First patient dosed in Phase 3 ASP2138 gastric cancer study

KEY STEP

Astellas announced that the first patient was dosed in a Phase 3 study evaluating ASP2138 with chemotherapy and pembrolizumab as first line treatment for adults with CLDN18.2 positive and HER2 negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Roadmap reference
People

Company team

ES

Eriko Sakurai

Independent Outside Director

Company leadership profile.

AE

Andreas Eugen Busch

Independent Outside Director

Company leadership profile.

KY

Kenji Yasukawa

Chairman of the Board

Company leadership profile.

NO

Naoki Okamura

President, CEO & Representative Director

Company leadership profile.

KS

Katsuyoshi Sugita

Executive VP, Chief People Officer & Representative Director

Company leadership profile.

TT

Takashi Tanaka

Independent Outside Director

Company leadership profile.

RH

Rika Hirota

Director

Company leadership profile.

RA

Rie Akiyama

Outside Independent Director

Company leadership profile.

YO

Yoichi Ohno

Outside Independent Director

Company leadership profile.

MM

Masahiro Miyazaki

Outside Independent Director

Company leadership profile.

TA

Tomoko Aramaki

Outside Independent Director

Company leadership profile.

MJ

Mark Joseph Enyedy

Independent Outside Director

Company leadership profile.

ST

Shigeki Takahara

Independent Outside Director

Company leadership profile.

Expert coverage

1 expert evaluated Astellas Pharma.

Orbitrum research

Experts evaluating Astellas Pharma

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment